Diagnosis of Heart Failure with Preserved Ejection Fraction

被引:20
|
作者
Wachter, Rolf [1 ]
Edelmann, Frank [1 ]
机构
[1] Univ Gottingen, Clin Cardiol & Pneumol, DZHK German Ctr Cardiovasc Res, D-37073 Gottingen, Germany
关键词
Heart failure with preserved ejection fraction; Diastolic heart failure; Diagnosis; Biomarkers; Echocardiographic; Diastolic dysfunction; EUROPEAN-SOCIETY; TASK-FORCE; SPIRONOLACTONE; HYPERTENSION; PREVALENCE; GUIDELINES; OUTCOMES;
D O I
10.1016/j.hfc.2014.04.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heart failure with preserved ejection fraction (HFpEF) constitutes a growing health care burden worldwide. Although definitions vary somewhat among guidelines, in general the presence of typical heart failure symptoms and signs in combination with a preserved left ventricular ejection fraction (>= 50%) and functional and/or structural left ventricular changes makes the diagnosis likely. This review focuses on the current understanding of diagnostic criteria, as presented in current guidelines and consensus recommendations, and on new insights from recent papers. The role of comorbidities that often contribute to symptoms and hamper the HFpEF diagnostics is also reviewed.
引用
收藏
页码:399 / +
页数:9
相关论文
共 50 条
  • [1] Epidemiology and clinical course of heart failure with preserved ejection fraction
    Lam, Carolyn S. P.
    Donal, Erwan
    Kraigher-Krainer, Elisabeth
    Vasan, Ramachandran S.
    EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (01) : 18 - 28
  • [2] Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction
    Zordoky, Beshay N.
    Sung, Miranda M.
    Ezekowitz, Justin
    Mandal, Rupasri
    Han, Beomsoo
    Bjorndahl, Trent C.
    Bouatra, Souhaila
    Anderson, Todd
    Oudit, Gavin Y.
    Wishart, David S.
    Dyck, Jason R. B.
    PLOS ONE, 2015, 10 (05):
  • [3] Pharmacotherapy of Heart Failure with Preserved Ejection Fraction
    Basaraba, Jade E.
    Barry, Arden R.
    PHARMACOTHERAPY, 2015, 35 (04): : 351 - 360
  • [4] Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction
    Rossignol, Patrick
    Claggett, Brian Lee
    Liu, Jiankang
    Vardeny, Orly
    Pitt, Bertram
    Zannad, Faiez
    Solomon, Scott
    AMERICAN JOURNAL OF HYPERTENSION, 2018, 31 (04) : 407 - 414
  • [5] Diagnosis and treatment of heart failure with preserved ejection fraction
    辛坤丽
    张金国
    SouthChinaJournalofCardiology, 2015, 16 (03) : 193 - 200
  • [6] Heart Failure with Preserved Ejection Fraction: Diagnosis and Management
    Oren, Ohad
    Goldberg, Sheldon
    AMERICAN JOURNAL OF MEDICINE, 2017, 130 (05) : 510 - 516
  • [7] Curative effect analysis of urapidil on heart failure with preserved ejection fraction and heart failure with reduced ejection fraction
    Yuan, Xiao-Ye
    Ding, Cun-Tao
    Li, Jing
    Tan, Jing
    Wang, Yan-Ling
    Fan, Zhen-Xing
    He, Jing-Yu
    Yang, Wei
    Hua, Qi
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (01): : 494 - 503
  • [8] Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment
    von Haehling, Stephan
    Assmus, Birgit
    Bekfani, Tarek
    Dworatzek, Elke
    Edelmann, Frank
    Hashemi, Djawid
    Hellenkamp, Kristian
    Kempf, Tibor
    Raake, Philipp
    Schuett, Katharina A.
    Wachter, Rolf
    Schulze, Paul Christian
    Hasenfuss, Gerd
    Boehm, Michael
    Bauersachs, Johann
    CLINICAL RESEARCH IN CARDIOLOGY, 2024, 113 (09) : 1287 - 1305
  • [9] Hypertension and Heart Failure with Preserved Ejection Fraction
    Lee, Chan Joo
    Park, Sungha
    HEART FAILURE CLINICS, 2021, 17 (03) : 337 - 343
  • [10] Pathophysiology of Heart Failure with Preserved Ejection Fraction
    Youn, Jong-Chan
    Ahn, Yuran
    Jung, Hae Ok
    HEART FAILURE CLINICS, 2021, 17 (03) : 327 - 335